ABSTRACT:The present study is an attempt to develop a Matrix type transdermal system capable of delivering the selected antidiabetic drug Repaglinide in the desired therapeutic concentration for prolong period. The principle of transdermal drug delivery systems is to deliver drug across epidermis to achieve systemic effect over a prolonged period of time. Because of these attributes, transdermal drug delivery systems offer many advantages such as reduced side effects, improved patient compliance, elimination of first-pass metabolism, and sustained drug delivery. Antidiabetic drug which is important for the treatment of hyperglycemic disorders. This category of anti-diabetic drugs is rapid and almost completely absorbed from the GIT following oral administration, but undergoes extensive first pass metabolism. Therefore, the peak plasma concentration occurs rapidly and after a single oral dose and bioavailability is 56%, the half-life of elimination is 1 hour in normal subject. Hence, it is required to design a drug delivery system which may deliver anti-diabetic drug Repaglinide in controlled manner for a prolonged period to circumvent the drug related side effects. Considering all these problems associated with oral administration of anti-diabetic drug Repaglinide, attempt has been made to develop transdermal drug delivery system in order to achieve a better release pattern.
INTRODUCTION
Transdermal is a viable administration route for potent, low molecular weight therapeutic agents which cannot withstand the hostile environment of the gastrointestinal tract and/or are subject to considerable first-pass metabolism by the liver.Globally, the occurrence of diabetes is increasing at an alarming rate. Type-II diabetes represents about 98% of all diabetes cases, in population older than 45 years of age.
Medication-related problems leading to morbidity and mortality are quite common with the disease. For diabetic patients, medication becomes an integral part of life and noncompliance of therapy may lead to chronic complications. Management strategies need to tackle public-health issues such as obesity and lack of exercise as well as incorporating drugs that address the underlying pathophysiology of type-II diabetes.
Fortunately, our understanding of that pathophysiology is now becoming clearer and this knowledge is to yield new agents of therapeutic promise such as Repaglinide.
Repaglinide is a short-acting oral hypoglycemic agent used as a prandial glucose regulator in the management of type -II diabetes mellitus. The drug possesses low oral bioavailability (56 %) due to hepatic first pass metabolism after oral administration and poor absorption in the upper intestinal tract. It has a very short biological half-life of ~1h, which makes frequent dosing necessary to maintain the drug within the therapeutic blood level for longer period.
Moreover, it produces hypoglycemia; causes gastrointestinal adverse effects including abdominal pain, diarrhoea, constipation, nausea and vomiting after oral administration. Because diabetes is a chronic disease hence the treatment is intended over a prolonged period.
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Transdermal delivery systems may provide a useful drug therapy about patient compliance. Transdermal delivery can bypass the first pass metabolism and deliver the drug in a ratecontrolled manner, which is desirable in anti-diabetic therapy. With this view, an attempt will be made to deliver Repaglinide in effective therapeutic concentration in TDDS form [1] [2] [3] [4] [5] .
MATERIALS & METHODS

Materials
Repaglinide was obtained as a gift sample from Alkem Laboratories, Mumbai. Eudragit RS 100, Eudragit RL100 & HPMC from Evonik Degussa India pvt.Ltd.,Mumbai. Double Distilled water was used throughout the study & all other chemicals and solvents were analytical reagent grade and purchased from commercial suppliers.
Methods
Preparation of Transdermal patches[6-8]
The transdermal patches were prepared by solvent evaporation method. Different polymers (Eudragit RS 100, Eudragit RL 100 and HPMC) alone and in combination were accurately weighed and dissolved in 20 ml solvent. Known volume of Dibutyl pthalate was used as plasticizer and oleic acid used as permission enhancer and mixed thoroughly with help of magnetic stirrer. 90 mg of drug was dissolved in the solution and mixed for 10mins. The resulted uniform solution was poured into petri-dish and kept for the evaporation after 24hrs a dried film were out and stored in desiccators. 
Evaluation of Transdermal patches
The prepared Repaglinide transdermal patches were evaluated as mentioned below. Transdermal patches of Repaglinide were prepared by using polymers, like HPMC, Eudragit RL100 and Eudragit RS100. The patches were transparent, smooth and flexible. The results of weight variation, thickness, moisture content, moisture uptake, Folding Endurance, drug content was calculated. The patches F1 to F7exhibited uniform weight ranging from 137.4 mg to 271.4 mg and thickness of F1 to F7 are ranging from 0.14 to 0.22mm. Among the various batches, the uniformity weight and thickness indicates that the polymeric solution of the drug is well dispersed in the patches. All the formulations (F1 to F7) exhibited fairly uniform drug content ranging from 93.1% to 98.4% respectively.
The moisture uptake and Moisture content was found to be low in formulation F3, F4, F5, F6 and F7. This is because of hydrophobic nature of Eudragit polymer compared to HPMC. Folding Endurance of the developed formulations F1 to F7 varied from 205.2 to 243.6. The highest folding endurance was noted for formulation F6.The in vitro permeation studies of patches using cellophane membrane barrier was carried out using modified diffusion cell.
The cumulative percentage of drug permeated from F1 to F7 formulations was given in the following order F1 > F2 > F3 > F7> F4 > F5> F6. From the graph, it is evident that drug release is decreased with the increase in concentration of polymer. Eudragit RS 100 and Eudragit RL100 patches have also shown decreased drug release when compared to HPMC patches. The 'n' values are in between 0.5 to 1, so the release is following non-Fickian, diffusion controlled kinetics. The stability studies were carried out on the most satisfactory formulations F6 at 30 ± 2°C/ 65 ± 5% RH and 40 ± 2°C/ 75 ± 5% RH for two months to assess their long-term stability as per ICH guidelines. At fixed time intervals of 30 days and 60 days, the formulation was evaluated for the physicochemical properties. There was no significant difference in the physicochemical Parameters and were found to be super impossible with the initial readings at zero day results.
CONCLUSION
The preformulation studies involving description, solubility, melting point, of the drug were found to be comparable with the standard. Based on the all the above preformulation studies the drug was suitable for making the transdermal formulation. Based on all these factors the transdermal drug delivery system F1 is having greater % drug release. Formulation F6 having less drug release capacity than other formulations. The formulation F6 shows better extended release up to 12 hrs when compared to other formulations. So, it was concluded that the formulation F6 prepared by using Eudragit RS 100(1:2 ratio)is the better formulation for control release of drug up to 12 hrs of time.
However, the in vitro drug release of the best formulation F6 follows first order kinetics and the mechanism of diffusion.
Results of the present study encouraged that the Repaglinide with Eudragit RS 100 transdermal patch can be used as controlled drug delivery system and frequency of administration can be minimized.
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